Regeneron Pharmaceuticals
Innovative biotech known for Eylea (eye disease), Dupixent (eczema/asthma, with Sanofi), and COVID-19 antibody treatments.
Services Offered
Our Take
Regeneron makes game-changing drugs for conditions that used to have limited options. Eylea transformed treatment for macular degeneration. Dupixent (with Sanofi) has been life-changing for severe eczema and asthma patients. Their patient support programs - EYLEA4U and Dupixent MyWay - help with copays and access.
Pros
- ✓Innovative drugs for underserved conditions
- ✓EYLEA4U copay assistance
- ✓Dupixent MyWay program
- ✓Strong R&D pipeline
- ✓Good patient support navigation
Cons
- ✗Dupixent expensive without coverage
- ✗Specialty drugs require specific access
- ✗Insurance coverage varies
- ✗Prior authorization common
Pricing Details
EYLEA4U and Dupixent MyWay programs provide copay assistance and patient support. My Regeneron Support offers navigation help.
Best For
- • Eye diseases (macular degeneration)
- • Severe eczema
- • Uncontrolled asthma
- • Allergies
Coverage
- 📍 Global
Accreditations
- ✓FDA approved
- ✓Best-in-class for Dermatology (PURE 2024, with Sanofi)
Trust Indicators
Years in Business
36+
Last verified: December 21, 2024
⚠️ Important
Always verify pricing and details directly with the provider. Prices shown are estimates based on our research as of December 2024 and may have changed.
This information is for educational purposes only and does not constitute medical advice. Consult with qualified healthcare professionals before making medical decisions.
We may earn a commission if you use our links, but this does not affect our editorial opinions or the information presented.
Opens in new window • direct link